Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence

Multiple biomarkers are needed to distinguish aggressive from indolent prostate cancer. We tested the prognostic utility of a three-marker fluorescent in situ hybridization panel (TMPRSS2/ERG rearrangements, AR gain, and PTEN deletion) in a retrospective cohort (n = 210; median follow-up, 5.7 years). PTEN deletion was associated with an increased risk of biochemical recurrence (BcR; hazard ratio, 3.58; 95% CI, 1.39–9.22; P 

Source: Journal of Molecular Diagnostics - January 2, 2016 Category: Pathology Authors: Xiaoyu Qu, Claudio Jeldres, Lena Glaskova, Cynthia Friedman, Sarah Schroeder, Peter S. Nelson, Christopher Porter, Min Fang Tags: Regular Article Source Type: research